1 / 13

Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases

Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases. Birgitta Maćešić, Mirica Rapić. Introduction. Chronic obstructive airway diseases (asthma and COPD) COPD – prevalence 4% - 10% (increasing) COPD - the fifth cause of death (WHO)

adivers
Télécharger la présentation

Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases Birgitta Maćešić, Mirica Rapić

  2. Introduction • Chronic obstructive airway diseases (asthma and COPD) • COPD – prevalence 4% - 10% (increasing) • COPD - the fifth cause of death (WHO) • COPD – low quality of life • COPD - absenteism and invalidity

  3. Aims and purpose To investigate morbidity and mortality trends and utilisation of anti-asthmatics in Croatia, 2006 - 2015 The obtained results might be useful in raising the awareness if anti-asthmatics drug’s utilisation is in accordance to evidence based knowledge and to forecast a future trends important for family doctors and decision makers

  4. Method • Primary Health Care (PHC) morbidity data – Croatian Health-service Yearbooks, 2006 – 2015 • ICD-X – respiratory - J diagnostic codes • J40 - J47 codes (asthma and COPD) – one group • Mortality data – Annual Reports of Croatian Institute for Public Health • Specific mortality – obstructive pulmonary diseases

  5. Anti-asthmatic drugs utilisation data • Annual Reports of Croatian Agency for Medicinal Products and Medical Devices, 2006 - 2015 • Anatomic-therapeutic clasification (ATC) index • Defenied daly doses/1000/day (DDD/TID)

  6. Anti-asthmatics • Respiratory – R, R03 – antiasthamtics • R03AC - Saba, Laba, • R03BA – glukocorticoids, • R03BB - anticholinergics (Sama, Lama), • R03AK - adrenergics + corticosteroids, • R03AL - adrenergics i anticholinergics, • R03DA - xanthines, • R03DC - Leukotriene receptor antagonists, R03DX - Other - omalizumab, roflumilast

  7. Results • Morbidity • Drug utilisation • Mortality

  8. Morbidity of chronic obstructive airway diseases (J40 – J47)

  9. Total drug utilisation – R03

  10. Utilisation of specific groups

  11. Mortality

  12. Conclusions • Decreased morbidity trend • Increased drug utilisation • Higher increase in the groups of: anticholinergics (R03BB) by 4,14 times; glucocorticoids (R03BA) by 2,24 times; Leukotriene receptor antagonists ( R03DC) by 1,56 times • Increased mortality trend

  13. For communication • Birgitta Maćešić, bacc. med. techn., Specijalistička ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac • Mirica Rapić, specialist of Family Medicine, Specijalisitčka ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac • e-mail: mirica.rapic@ka.t-com.hr

More Related